Medtronic has announced that it will unveil results, in a late-breaking trial session on Tuesday 29 October, from its Extreme Risk study of the CoreValve US Pivotal Trial at the annual Transcatheter Cardiovascular Therapeutics (TCT) conference (27 October–1 November, San Francisco, USA).
“Unveiling the CoreValve US Pivotal Trial data for the first time is a significant milestone as we work toward bringing more therapy options to patients in the USA,” says John Liddicoat, senior vice president, Medtronic, and president of the Medtronic Structural Heart Business at Medtronic. “This study will provide vital information for physicians and their US patients, many of whom have had no good option for treating their aortic stenosis.”
Also during another late-breaking clinical trials session at TCT, there will be two presentations involving Medtronic drug-eluting stents:
- Conducted in Brazil, the OPTIMIZE study compared one-year outcomes in patients who received the Endeavor drug-eluting stent and stayed on dual antiplatelet therapy for either three or 12 months. It is the largest prospective randomised drug-eluting stent trial.
- Conducted in the Netherlands, the DUTCH PEERS study compared one-year outcomes in patients who received either the Resolute Integrity drug-eluting stent or the Promus Element drug-eluting from Boston Scientific. It is the first prospective randomised controlled trial of “third-generation” drug-eluting stents.
